Skip to main content
XCUR
NASDAQ Life Sciences

Exicure Appoints New CEO and Interim CFO, Filling Key Leadership Vacancies

Analysis by Wiseek.ai
Sentiment info
Positive
Importance info
8
Price
$3.81
Mkt Cap
$24.762M
52W Low
$3.101
52W High
$15.91
Market data snapshot near publication time

summarizeSummary

Exicure, Inc. has appointed Jung Soo Kim as its new CEO and President, and Gyuyeob Lee as Interim CFO and Secretary, effectively filling the critical leadership positions that were recently vacated.


check_boxKey Events

  • New CEO Appointed

    Jung Soo Kim has been appointed as the Chief Executive Officer and President of Exicure, Inc., effective February 11, 2026.

  • Interim CFO Appointed

    Gyuyeob Lee has been appointed as the Interim Chief Financial Officer and Secretary of the Company, also effective February 11, 2026.

  • Leadership Vacancies Filled

    These appointments resolve the C-suite vacancies that resulted from the resignations of the previous CEO and CFO, which were announced in an 8-K filing on February 10, 2026.

  • Executive Services Agreements

    The services for the new CEO and Interim CFO will be provided to the Company pursuant to executive services agreements with Innocircle Advisors Inc.


auto_awesomeAnalysis

This 8-K filing addresses the significant leadership vacuum created by the resignations of the previous CEO and CFO, which were disclosed in a prior 8-K on February 10, 2026. The appointment of Jung Soo Kim as CEO and President, and Gyuyeob Lee as Interim CFO and Secretary, provides much-needed stability and direction for the company. For a micro-cap company like Exicure, Inc., having a complete executive team is crucial for operational continuity and investor confidence, especially following recent significant shareholder sales and a clinical trial milestone. The new executives bring experience in corporate strategy, capital markets, and financial management, which could be vital for the company's future.

At the time of this filing, XCUR was trading at $3.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24.8M. The 52-week trading range was $3.10 to $15.91. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed XCUR - Latest Insights

XCUR
Apr 22, 2026, 7:57 PM EDT
Source: Reuters
Importance Score:
8
XCUR
Apr 10, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
7
XCUR
Apr 02, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
8
XCUR
Mar 27, 2026, 4:43 PM EDT
Source: Wiseek News
Importance Score:
7
XCUR
Mar 27, 2026, 4:40 PM EDT
Filing Type: 8-K
Importance Score:
7
XCUR
Mar 25, 2026, 4:42 PM EDT
Filing Type: 10-K
Importance Score:
9
XCUR
Mar 25, 2026, 4:32 PM EDT
Filing Type: 8-K
Importance Score:
9
XCUR
Mar 25, 2026, 4:18 PM EDT
Source: GlobeNewswire
Importance Score:
9
XCUR
Feb 17, 2026, 5:25 PM EST
Filing Type: 8-K
Importance Score:
8
XCUR
Feb 10, 2026, 4:25 PM EST
Filing Type: 8-K
Importance Score:
9